This program will collect safety information and allow the treating physicians to attempt a maximum dexamethasone reduction and possible elimination altogether. Xerecept will be provided to patients until either the drug becomes commercially available or until research in this indication is discontinued.
Dr Lisa Carr, Sr vice president and chief medical officer of NTI, said, “We are pleased to offer the extended-use of this potential dexamethasone-sparing agent to patients in all of our trials.”
Neurobiological Technologies is an emerging drug development company focused on the clinical evaluation and regulatory approval of neuroscience drugs. The company’s strategy is to in-license and develop early- and later-stage drug candidates that target major medical needs and which can be rapidly commercialized.